Total Payments
$487,145
2024 Payments
$95,991
Companies
40
Transactions
498
Medicare Patients
2,032
Medicare Billing
$231,959
Payment Breakdown by Category
Other$371,636 (76.3%)
Travel$72,384 (14.9%)
Consulting$30,331 (6.2%)
Food & Beverage$12,215 (2.5%)
Education$578.33 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $371,636 | 130 | 76.3% |
| Travel and Lodging | $72,384 | 97 | 14.9% |
| Consulting Fee | $30,331 | 25 | 6.2% |
| Food and Beverage | $12,215 | 233 | 2.5% |
| Education | $578.33 | 13 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $184,043 | 155 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $119,593 | 94 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $80,000 | 51 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $68,001 | 51 | $0 (2020) |
| GENZYME CORPORATION | $12,904 | 19 | $0 (2024) |
| Mirati Therapeutics, Inc. | $10,454 | 10 | $0 (2023) |
| Eisai Inc. | $3,595 | 5 | $0 (2024) |
| Exelixis Inc. | $1,980 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $1,665 | 12 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $1,616 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95,991 | 128 | E.R. Squibb & Sons, L.L.C. ($39,820) |
| 2023 | $133,774 | 112 | AstraZeneca Pharmaceuticals LP ($59,873) |
| 2022 | $83,660 | 79 | E.R. Squibb & Sons, L.L.C. ($37,491) |
| 2021 | $70,672 | 61 | AstraZeneca Pharmaceuticals LP ($35,146) |
| 2020 | $29,116 | 30 | AstraZeneca Pharmaceuticals LP ($20,494) |
| 2019 | $28,406 | 36 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,644) |
| 2018 | $26,280 | 29 | Boehringer Ingelheim Pharmaceuticals, Inc. ($25,919) |
| 2017 | $19,246 | 23 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,338) |
All Payment Transactions
498 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $1,144.41 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.42 | General |
| Category: Hematology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $96.48 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Oncology | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.21 | General |
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $1,791.05 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $118.76 | General |
| Category: Oncology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.57 | General |
| Category: Oncology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $1.07 | General |
| Category: Oncology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $1.06 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,912.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $31.15 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: DESMOID TUMORS | ||||||
| 11/07/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.71 | General |
| Category: Hematology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $204.06 | General |
| Category: Oncology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $116.90 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Oncology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $9.47 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $4.71 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Oncology | ||||||
| 11/04/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 508 | 771 | $146,236 | $53,050 |
| 2022 | 10 | 499 | 813 | $165,148 | $61,601 |
| 2021 | 11 | 521 | 862 | $167,203 | $65,854 |
| 2020 | 9 | 504 | 838 | $147,827 | $51,454 |
Total Patients
2,032
Total Services
3,284
Medicare Billing
$231,959
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 81 | 164 | $45,428 | $17,832 | 39.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 130 | 245 | $49,000 | $17,354 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 175 | 227 | $31,780 | $9,315 | 29.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 20 | 25 | $3,250 | $1,604 | 49.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $3,762 | $1,537 | 40.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $4,352 | $1,528 | 35.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 19 | $2,318 | $1,164 | 50.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $2,574 | $1,107 | 43.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 15 | 22 | $1,540 | $843.92 | 54.8% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 31 | 31 | $2,232 | $763.96 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 85 | 240 | $66,480 | $26,238 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 141 | 258 | $51,600 | $17,922 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 143 | 167 | $23,380 | $7,682 | 32.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $7,524 | $2,859 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,044 | $1,854 | 45.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 19 | $3,306 | $1,519 | 46.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 22 | $2,860 | $1,142 | 39.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 15 | $1,830 | $832.94 | 45.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 22 | 26 | $1,820 | $784.65 | 43.1% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Facility | 2022 | 32 | 32 | $2,304 | $766.87 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 158 | 331 | $64,160 | $24,335 | 37.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 82 | 194 | $51,498 | $20,702 | 40.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 125 | 146 | $19,930 | $7,093 | 35.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 34 | $5,916 | $2,775 | 46.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 20 | 29 | $5,365 | $2,657 | 49.5% |
About Dr. Anush Patel, M.D
Dr. Anush Patel, M.D is a Hematology & Oncology healthcare provider based in Cooperstown, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1790986081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anush Patel, M.D has received a total of $487,145 in payments from pharmaceutical and medical device companies, with $95,991 received in 2024. These payments were reported across 498 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($371,636).
As a Medicare-enrolled provider, Patel has provided services to 2,032 Medicare beneficiaries, totaling 3,284 services with total Medicare billing of $231,959. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cooperstown, NY
- Active Since 05/31/2007
- Last Updated 08/09/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1790986081
Products in Payments
- OPDIVO (Biological) $108,868
- LIBTAYO (Biological) $92,492
- TAGRISSO (Drug) $86,488
- IMFINZI (Biological) $68,748
- GILOTRIF (Drug) $68,001
- IMFINZI (Drug) $20,727
- KRAZATI (Drug) $10,454
- AUGTYRO (Drug) $6,716
- CALQUENCE (Drug) $4,504
- Halaven (Drug) $3,420
- CABOMETYX (Drug) $1,980
- XPOVIO (Drug) $1,616
- ENHERTU (Biological) $468.69
- Revlimid (Drug) $295.57
- JEVTANA (Drug) $236.30
- Rubraca (Drug) $224.00
- RYBREVANT (Drug) $201.95
- Lenvima (Drug) $175.13
- REBLOZYL (Biological) $154.15
- SARCLISA (Biological) $146.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.